Alnylam's Cardiovascular siRNA Program Hits Phase 3 Primary Endpoint

The RNA interference pioneer reports positive topline data for its Lp(a)-targeting siRNA in cardiovascular disease, validating oligonucleotide approaches beyond rare disease and into large patient populations.